NL-OMON28193招募中不适用
Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry
EHA Lymphoma group0 个研究点目标入组 500 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy, All stages at the time of relapse, Histological grade 1-3a at the time of initial diagnosis, Age over 18 years, Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested, Diagnostic material available for review, Written informed consent.
排除标准
- •Age < 18 years
研究者
相似试验
进行中（未招募）
1 期
Tirzepatide, a new drug for type 2 diabetes mellitus and obesity, as a possible treatment to modify the clinical evolution of Wolfram syndrome type 1CTIS2024-514909-64-00Ospedale San Raffaele S.r.l.10
招募中
不适用
Personalized neurorehabilitative precision medicine – from data to therapiesI61I62Intracerebral haemorrhageOther nontraumatic intracranial haemorrhageDRKS00025132eurologische Universitätsklinik und Hertie-Institut für Klinische Hirnforschung500
已完成
3 期
Strategies for improving blood pressure control in AfricaResistant hypertensionISRCTN69440037Grand Challenges Canada120
招募中
不适用
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae RegistryRelapsed/Refractory Follicular LymphomaFollicular LymphomaNCT04587388European Hematology Association - Lymphoma Group500
进行中（未招募）
1 期
aEUCTR2015-000982-30-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE168